Kanuma

Sebelipase alfa, the active ingredient in Kanuma, is an enzyme replacement therapy presented as a solution for injection for intravenous use. It is indicated for lysosomal acid lipase deficiency, including Wolman disease and cholesteryl ester storage disease, in patients with these rare metabolic disorders.

GNH USA supplies Kanuma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance and quality assurance.

Kanuma is used to treat lysosomal acid lipase deficiency, a rare lysosomal storage disorder. - Wolman disease: reduces accumulation of cholesteryl esters and triglycerides in organs, improving liver function and survival. - Cholesteryl ester storage disease (CESD): decreases hepatic lipid storage, helping to normalize liver enzymes and lipid profiles. - Lysosomal acid lipase deficiency (overall): restores deficient enzyme activity, mitigating disease progression.

Adverse reactions reported with Kanuma are generally related to the infusion process or immune response.

Common Side Effects: - Infusion‑related reactions: flushing, chills, fever, or headache during or shortly after administration. - Gastrointestinal symptoms: nausea, vomiting, abdominal pain, or diarrhea. - Respiratory symptoms: cough, dyspnea, or nasal congestion.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions requiring immediate medical attention. - Development of anti‑sebelipase alfa antibodies that may reduce efficacy. - Hepatic enzyme elevations indicating liver stress. - Thrombotic events such as deep vein thrombosis (rare).

When using Kanuma, clinicians should observe several precautionary measures to ensure patient safety and product integrity. - Pre‑infusion assessment: evaluate patient for known hypersensitivity to recombinant proteins. - Monitoring during infusion: observe vital signs and watch for infusion‑related reactions. - Antibody testing: consider periodic assessment for anti‑drug antibodies that could affect response. - Liver function: check baseline and periodic liver enzymes due to potential hepatic effects. - Concomitant medications: review for agents that may increase risk of hypersensitivity or interfere with immune response. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Kanuma may interact with other medicines, primarily through immunologic or metabolic pathways.

Major Interactions (Avoid): - Live vaccines: concurrent use may increase risk of vaccine‑related infection due to immune modulation. - Immunosuppressive biologics: combined therapy can heighten risk of severe immune reactions.

Moderate Interactions (Monitor Closely): - Antihistamines or corticosteroids: may mask infusion‑related symptoms, requiring careful monitoring. - Lipid‑lowering agents (e.g., statins): monitor liver enzymes as both may affect hepatic function. - Concomitant enzyme replacement therapies: assess for overlapping immune responses.